- Home
- HRMY vs BANR Comparison
HRMY vs BANR Comparison
Compare HRMY & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- BANR
- Stock Information
- Founded
- HRMY 2017
- BANR 1890
- Country
- HRMY United States
- BANR United States
- Employees
- HRMY N/A
- BANR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- BANR Major Banks
- Sector
- HRMY Health Care
- BANR Finance
- Exchange
- HRMY Nasdaq
- BANR Nasdaq
- Market Cap
- HRMY 1.5B
- BANR 2.2B
- IPO Year
- HRMY 2020
- BANR 1995
- Fundamental
- Price
- HRMY $28.86
- BANR $60.68
- Analyst Decision
- HRMY Strong Buy
- BANR Buy
- Analyst Count
- HRMY 10
- BANR 5
- Target Price
- HRMY $50.80
- BANR $71.50
- AVG Volume (30 Days)
- HRMY 813.6K
- BANR 259.4K
- Earning Date
- HRMY 11-04-2025
- BANR 10-15-2025
- Dividend Yield
- HRMY N/A
- BANR 3.29%
- EPS Growth
- HRMY 58.41
- BANR 14.84
- EPS
- HRMY 3.10
- BANR 5.49
- Revenue
- HRMY $772,527,000.00
- BANR $640,027,000.00
- Revenue This Year
- HRMY $20.10
- BANR $0.69
- Revenue Next Year
- HRMY $16.50
- BANR $7.83
- P/E Ratio
- HRMY $9.34
- BANR $11.07
- Revenue Growth
- HRMY 17.74
- BANR 7.86
- 52 Week Low
- HRMY $25.52
- BANR $54.01
- 52 Week High
- HRMY $40.93
- BANR $78.05
- Technical
- Relative Strength Index (RSI)
- HRMY 49.49
- BANR 33.66
- Support Level
- HRMY $25.52
- BANR $60.57
- Resistance Level
- HRMY $30.96
- BANR $64.73
- Average True Range (ATR)
- HRMY 0.85
- BANR 1.67
- MACD
- HRMY 0.51
- BANR -0.16
- Stochastic Oscillator
- HRMY 57.54
- BANR 1.96
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.